Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale School of Medicine, New Haven, Connecticut, USA.
Epidemiology Program, School of Public Health, Louisiana State University Health Sciences Center-New Orleans, New Orleans, Louisiana, USA.
Prostate. 2023 Jan;83(1):44-55. doi: 10.1002/pros.24434. Epub 2022 Sep 5.
Financial toxicity (FT) is a growing concern among cancer survivors that adversely affects the quality of life and survival. Individuals diagnosed with aggressive cancers are often at a greater risk of experiencing FT. The objectives of this study were to estimate FT among prostate cancer (PCa) survivors after 10-15 years of diagnosis, assess the relationship between PCa aggressiveness at diagnosis and FT, and examine whether current cancer treatment status mediates the relationship between PCa aggressiveness and FT.
PCa patients enrolled in the North Carolina-Louisiana Prostate Cancer Project (PCaP) were recontacted for long-term follow-up. The prevalence of FT in the PCaP cohort was estimated. FT was estimated using the COmprehensive Score for Financial Toxicity, a validated measure of FT. The direct effect of PCa aggressiveness and an indirect effect through current cancer treatment on FT was examined using causal mediation analysis.
More than one-third of PCa patients reported experiencing FT. PCa aggressiveness was significantly independently associated with high FT; high aggressive PCa at diagnosis had more than twice the risk of experiencing FT than those with low or intermediate aggressive PCa (adjusted odds ratio [aOR] = 2.13, 95% CI = 1.14-3.96). The proportion of the effect of PCa aggressiveness on FT, mediated by treatment status, was 10%, however, the adjusted odds ratio did not indicate significant evidence of mediation by treatment status (aOR = 1.05, 95% CI = 0.95-1.20).
Aggressive PCa was associated with high FT. Future studies should collect more information about the characteristics of men with high FT and identify additional risk factors of FT.
财务毒性(FT)是癌症幸存者日益关注的问题,它会对生活质量和生存产生不利影响。被诊断患有侵袭性癌症的个体往往面临更大的 FT 风险。本研究的目的是在诊断后 10-15 年内估计前列腺癌(PCa)幸存者的 FT,评估诊断时 PCa 侵袭性与 FT 的关系,并检验当前癌症治疗状况是否调节 PCa 侵袭性与 FT 的关系。
重新联系参加北卡罗来纳州-路易斯安那州前列腺癌项目(PCaP)的 PCa 患者进行长期随访。估计 PCaP 队列中 FT 的患病率。使用财务毒性综合评分(COmprehensive Score for Financial Toxicity)来评估 FT,这是一种经过验证的 FT 衡量标准。使用因果中介分析来检验 PCa 侵袭性和当前癌症治疗对 FT 的直接影响和间接影响。
超过三分之一的 PCa 患者报告经历了 FT。PCa 侵袭性与高 FT 显著独立相关;高侵袭性 PCa 诊断时经历 FT 的风险是低侵袭性或中侵袭性 PCa 的两倍多(调整后的优势比[aOR] = 2.13,95%可信区间[CI] = 1.14-3.96)。然而,治疗状况对 PCa 侵袭性对 FT 的影响的比例为 10%,但治疗状况的调整后的优势比并没有表明存在显著的中介证据(aOR = 1.05,95% CI = 0.95-1.20)。
侵袭性 PCa 与高 FT 相关。未来的研究应收集更多关于高 FT 男性特征的信息,并确定 FT 的其他危险因素。